Skip to main content
Equibles
NNVC logo

NNVC · Nanoviricides, Inc.

Track NNVC — free

Use NNVC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NNVC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.02 +0.00 (+0.00%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — flagged May 15, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management believes that the Company’s cash and cash equivalents balance of approximately $3.2 million, and the Company’s existing resources, including availability under its $3 million line of credit will not be sufficient to fund the Company’s planned operations and expenditures for at least 12 months from the date of the filing of this Form 10-Q. As a result, substantial doubt exists about the Company’s ability to continue as a going concern.”
View the 10-Q filed May 15, 2026
Market Cap
$22.08M
Shares
21.65M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.02 Open$1.02 Day$1.00–1.04 52W close$0.85–2.03 Avg vol 30d306K Short int646K · 3.0% float · 2.5d Short vol68% DataJan 2020–Sep 2026 Filing10-Q · May 15

Up next

Latest filing: 10-Q
filed May 15, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$8.09M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+34.8%
Year over year · more shares
Price change (1Y)
-28.7%
Trailing year
Short interest
3.0%
Latest settlement · 2.5 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −19%
below
Price vs 50-day avg −28%
below
RSI (14) 20
oversold
MACD trend Negative
52-week position 14%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −25%
trailing
6-month return −1%
trailing
YTD return −10%
this year
Relative strength −19%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.98% of float · ▼ -26.1% MoM · 2.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
48 holders — near 3-yr high, broad support
Squeeze score 39
low risk · 0–100
Fundamentals
Fair
EPS growth +10%
Y/Y
Free cash flow $-8.5M
Quant / Vol
risk profile
Very High
Volatility 87%
annualized · 1-yr
Max drawdown −58%
past year
ATR 7.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−19% Bearish
Price vs 50-day avg
−28% Bearish
RSI (14)
20 Neutral
MACD trend
Negative Bearish
52-week position
14% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.98% of float · ▼ -26.1% MoM · 2.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
48 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 14% Range high $2
vs 200-day avg -19% vs 50-day avg -28%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NNVC
Nanoviricides, Inc.
this stock
$22.08M -9.7% — — 3.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
48
% held
11.5%
Net QoQ
+559.5K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Falling
Shares short
646.1K
Days to cover
2.5d
Change
-227.9K sh
View
Short Volume
Short vol %
68%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
905
Value
$1.3K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
54.4%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-9.5M
EPS diluted
$-0.63
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 30, 2026
This year
6
View
Exempt Offerings
Offering
$6.0M
Filed
Feb 25, 2026
View

Performance

5D 20D 120D MTD YTD
NNVC -11.3% -25.0% -1.0% -18.4% -9.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -10.2% -23.3% -18.8% -18.0% -21.8%
Key facts CIK 1379006 CUSIP 630087302 13F (30d) 12 filings 12 filers Visit website Investor relations